{
    "eid": "2-s2.0-85066395588",
    "title": "Safety and immunogenicity of MF59-adjuvanted cell culture-derived A/H5N1 subunit influenza virus vaccine: Dose-finding clinical trials in adults and the elderly",
    "cover-date": "2019-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "cell culture-derived vaccine",
        "H5N1 subunit vaccine",
        "influenza",
        "MF59 adjuvant",
        "pandemic influenza",
        "phase II"
    ],
    "authors": [
        "Sharon E. Frey",
        "Sepehr Shakib",
        "Pornthep Chanthavanich",
        "Peter Richmond",
        "Timothy Smith",
        "Terapong Tantawichien",
        "Claudia Kittel",
        "Peter Jaehnig",
        "Zenaida Mojares",
        "Bikash Verma",
        "Niranjan Kanesa-Thasan",
        "Matthew Hohenboken"
    ],
    "citedby-count": 7,
    "ref-count": 28,
    "ref-list": [
        "Recognizing true H5N1 infections in humans during confirmed outbreaks",
        "Influenza: Options to improve pandemic preparation",
        "A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations",
        "MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database",
        "MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults",
        "Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults",
        "Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial",
        "Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine",
        "Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1",
        "The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly",
        "Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase clinical trial",
        "Immunogenicity of avian influenza A/ Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: A randomized clinical trial",
        "A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects",
        "Safety and immunogenicity of an MF59(\u00ae)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly",
        "Safety and immunogenicity of cell culture-derived A/H3N2 variant influenza vaccines: A phase I randomized, observer-blind, dose-ranging study",
        "Assessment of the immunogenicity and safety of varying doses of an MF59\u00ae-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects",
        "A randomized clinical trial to identify the optimal antigen and MF59(\u00ae) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects",
        "Immunogenicity and safety of cell-derived MF59\u00ae-adjuvanted A/H1N1 influenza vaccine for children",
        "Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age",
        "Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age",
        "Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age",
        "A dose-ranging study of MF59(\u00ae)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination",
        "Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children"
    ],
    "affiliation": [
        {
            "affiliation-city": "Zurich",
            "@id": "60113339",
            "affilname": "Takeda Pharma AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60113339",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60111449",
            "affilname": "GlaxoSmithKline, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60111449",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Philadelphia",
            "@id": "60097308",
            "affilname": "GlaxoSmithKline, USA",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60097308",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Perth",
            "@id": "60031806",
            "affilname": "The University of Western Australia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031806",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "St. Louis",
            "@id": "60028590",
            "affilname": "Saint Louis University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028590",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "St Peters",
            "@id": "122643050",
            "affilname": "StudyMetrix Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122643050",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Marburg",
            "@id": "122642954",
            "affilname": "GlaxoSmithKline Vaccines",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122642954",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Adelaide",
            "@id": "122642906",
            "affilname": "CMAX Clinical Research Pty Ltd",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122642906",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Lexington",
            "@id": "120805248",
            "affilname": "Kanesa LLC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/120805248",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Cambridge",
            "@id": "117807786",
            "affilname": "Seqirus Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117807786",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Berlin",
            "@id": "115052134",
            "affilname": "pj statistics",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115052134",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "St Louis",
            "@id": "100388806",
            "affilname": "Mercy Health Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100388806",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}